XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34(+)38(−) cells in a phase 1/2 study of patients with relapsed/refractory AML

Lignende værker

• Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia
  af: Schimmer, Aaron D., et al.
  Udgivet: (2009)
• Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
  af: Cummings, J, et al.
  Udgivet: (2005)
• Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
  af: Cummings, J, et al.
  Udgivet: (2006)
• Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish
  af: Pauli, Andrea, et al.
  Udgivet: (2015)
• XIAP Downregulation Promotes Caspase-dependent Inhibition of Proteasome Activity in AML Cells
  af: Carter, Bing Z., et al.
  Udgivet: (2013)